Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Jul 2017
At a glance
- Drugs Etanercept (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Amgen
- 05 Jul 2017 Planned End Date changed from 27 Nov 2017 to 19 Nov 2017.
- 05 Jul 2017 Planned primary completion date changed from 23 Aug 2017 to 15 Aug 2017.
- 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.